Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17541809 | 0.89 | TSHR (0.46) | CYP1A2ALDH1A1TSHRKCNH2KCNJ1 | |
| SCHEMBL904232 | 0.88 | ALDH1A1 (0.43) | ACHEHSD17B10CYP1A2CYP2A6TAAR1 | |
| SCHEMBL9356418 | 0.88 | IGF1R (0.47) | ACHEHSD17B10CYP1A2CYP2A6TAAR1 | |
| SCHEMBL19396020 | 0.83 | TAAR1 (0.46) | TAAR1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL19396004 | 0.83 | CA2 (0.48) | ALDH1A1TSHRKCNH2KCNJ1CNR2 | |
| SCHEMBL509775 | 0.79 | ALDH1A1 (0.52) | ACHEHSD17B10ALDH1A1LMNAKCNH2 | |
| SCHEMBL4543334 | 0.78 | ESR1 (0.54) | ACHEHSD17B10TAAR1ALDH1A1KMT2A | |
| SCHEMBL12708608 | 0.78 | TSHR (0.48) | CYP1A2ALDH1A1TSHRIDO1KCNH2 | |
| SCHEMBL2440720 | 0.78 | CYP1A2 (0.47) | CYP1A2TAAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL188308 | 0.78 | TSHR (0.64) | ALDH1A1TSHRIDO1KCNH2KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140228564-A1 | PROCESSES OF ENANTIOSELECTIVELY FORMING AN AMINOXY COMPOUND AND AN 1,2-OXAZINE COMPOUND | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-08-14 | — | — | US | disclosed |
| US-8680335-B2 | Processes of enantioselectively forming an aminoxy compound and an 1,2-oxazine compound | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-03-25 | — | — | US | disclosed |
| US-8540966-B2 | Contrast agents endowed with high relaxivity | BRACCO IMAGING S.P.A. (IT) | 2013-09-24 | — | — | US | disclosed |
| US-20110224429-A1 | PROCESSES OF ENANTIOSELECTIVELY FORMING AN AMINOXY COMPOUND AND AN 1,2-OXAZINE COMPOUND | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224429-A1 | PROCESSES OF ENANTIOSELECTIVELY FORMING AN AMINOXY COMPOUND AND AN 1,2-OXAZINE COMPOUND | AHR, CYP2S1, CYP1A1 | ACHE 1165/4885HSD17B10 516/4885CYP1A2 4/4885 |
| US-20140228564-A1 | PROCESSES OF ENANTIOSELECTIVELY FORMING AN AMINOXY COMPOUND AND AN 1,2-OXAZINE COMPOUND | AHR, CYP2S1, CYP1A1 | ACHE 1165/4885HSD17B10 516/4885CYP1A2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.